| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-01-13 | Merck KGaA (Germany) The University of Texas MD Anderson Cancer Center (USA - TX) | Adaptive Patient-Oriented Longitudinal Learning and Optimization Platform (APOLLO) | breast cancer, colorectal cancer, glioblastoma, leukemia | collaboration R&D | Cancer - Oncology | Collaboration agreement |
| 2017-01-12 | Biogen (USA - MA) Bioverativ (USA - CA) | spin-off of the hemophilia business (Bioverativ) | hemophilia A, hemophilia B | establishment of a new subsidiary in the US | Rare diseases - Genetic diseases - Hematological diseases | Establishment of a new subsidiary in the US |
| 2017-01-12 | Optibrium (UK) eMolecules (USA - CA) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2017-01-12 | Merck KGaA (Germany) Palantir Technologies (USA - CA) | collaboration |
Collaboration agreement | |||
| 2017-01-12 | Evotec (Germany) Haplogen (Austria) | small molecules against viral infectious diseases | viral infectious diseases | R&D |
Infectious diseases | R&D agreement |
| 2017-01-11 | Merck KGaA (Germany) Vertex Pharmaceuticals (USA - MA) | four research and development programs (VX-970, VX-803, VX-984) | development licensing commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2017-01-11 | Takeda Pharmaceutical (Japan) Maverick Therapeutics (USA - CA) | T-cell engagement platform | development |
Cancer - Oncology | Development agreement | |
| 2017-01-11 | Stellar Biotechnologies (USA - CA) BioEstelar (Mexico) | establishment of a new subsidiary |
Technology - Services | Establishment of a new subsidiary in the US | ||
| 2017-01-11 | Pierre Fabre Laboratories (France) Piqur Therapeutics (Switzerland) | PQR309 | development | Cancer - Oncology | Development agreement | |
| 2017-01-10 | Seqirus (Australia) Zambon (Italy) | Xadago™ (safinamide) | Parkinson’s disease | commercialisation |
Neurodegenerative diseases | Commercialisation agreement |
| 2017-01-10 | Merck KGaA (Germany) | opening of new premises |
Technology - Services | Opening of new premises | ||
| 2017-01-10 | Abbvie (USA - IL) Zebra Biologics (USA - MA) | antibody therapeutics | collaboration |
Inflammatory diseases | Collaboration agreement | |
| 2017-01-10 | Sarepta Therapeutics (USA - MA) Nationwide Children’s Hospital (USA - OH) | microdystrophin gene therapy program | Duchenne muscular dystrophy | R&D - clinical research | Rare diseases - Genetic diseases - Neuromuscular diseases | Clinical research agreement |
| 2017-01-10 | Sarepta Therapeutics (USA - MA) Nationwide Children’s Hospital (USA - OH) | Galgt2 gene therapy program | Duchenne muscular dystrophy | R&D licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases | Licensing agreement |
| 2017-01-10 | Ziopharm Oncology (USA - MA) Intrexon (USA - MD) National Cancer Institute (NCI) (USA) | adoptive cell transfer (ACT)-based immunotherapies genetically modified using the Sleeping Beauty (SB) transposon/transposase system | solid tumors | R&D |
Cancer - Oncology | R&D agreement |
| 2017-01-10 | Kite Pharma (USA - CA) Fosun Pharma (China) | axicabtagene ciloleucel (KTE-C19), KITE-439 and KITE-718 | joint-venture |
Cancer - Oncology | Joint-venture agreement | |
| 2017-01-09 | Innate Pharma (France) BMS (USA - NY) | IPH2102 (lirilumab) and related compounds blocking KIR receptors | hematologic cancers | development |
Cancer - Oncology | Milestone |
| 2017-01-09 | Aerie Pharmaceuticals (USA - CA) IDA Ireland (Ireland) | new manufacturing facility in Athlone | construction of new premises |
Ophtalmological diseases | Construction of new premises | |
| 2017-01-09 | Kite Pharma (USA - CA) Daiichi Sankyo (Japan) | axicabtagene ciloleucel (KTE-C19 (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) and atezolizumab | development - licensing - commercialisation | Cancer - Oncology - Rare diseases | Development agreement | |
| 2017-01-09 | Curis (USA - MA) Aurigene (India) | CA-170, CA-327 and CA-4948 | development licensing collaboration |
Cancer - Oncology | Licensing agreement |
